CA3155187A1 - Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 - Google Patents

Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 Download PDF

Info

Publication number
CA3155187A1
CA3155187A1 CA3155187A CA3155187A CA3155187A1 CA 3155187 A1 CA3155187 A1 CA 3155187A1 CA 3155187 A CA3155187 A CA 3155187A CA 3155187 A CA3155187 A CA 3155187A CA 3155187 A1 CA3155187 A1 CA 3155187A1
Authority
CA
Canada
Prior art keywords
domain
monomer
polypeptide
amino acid
domain monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3155187A
Other languages
English (en)
French (fr)
Inventor
Daniel ORTIZ
Amit Choudhury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Choudhury Amit
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choudhury Amit, Momenta Pharmaceuticals Inc filed Critical Choudhury Amit
Publication of CA3155187A1 publication Critical patent/CA3155187A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3155187A 2019-09-18 2020-09-18 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 Pending CA3155187A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902380P 2019-09-18 2019-09-18
US62/902,380 2019-09-18
PCT/US2020/051663 WO2021055876A1 (en) 2019-09-18 2020-09-18 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38

Publications (1)

Publication Number Publication Date
CA3155187A1 true CA3155187A1 (en) 2021-03-25

Family

ID=74884204

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3155187A Pending CA3155187A1 (en) 2019-09-18 2020-09-18 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38

Country Status (10)

Country Link
EP (1) EP4031166A1 (zh)
JP (1) JP2022548925A (zh)
KR (1) KR20220119362A (zh)
CN (1) CN114786713A (zh)
AU (1) AU2020351234A1 (zh)
BR (1) BR112022005036A2 (zh)
CA (1) CA3155187A1 (zh)
IL (1) IL291465A (zh)
MX (1) MX2022003316A (zh)
WO (1) WO2021055876A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103554259B (zh) * 2005-10-12 2016-05-18 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
RU2536937C2 (ru) * 2008-10-14 2014-12-27 Дженентек, Инк. Варианты иммуноглобулина и их применения
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
WO2015197582A1 (en) * 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
WO2018129397A1 (en) * 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs

Also Published As

Publication number Publication date
AU2020351234A1 (en) 2022-04-28
JP2022548925A (ja) 2022-11-22
CN114786713A (zh) 2022-07-22
EP4031166A1 (en) 2022-07-27
BR112022005036A2 (pt) 2022-07-05
IL291465A (en) 2022-05-01
WO2021055876A1 (en) 2021-03-25
MX2022003316A (es) 2022-07-11
KR20220119362A (ko) 2022-08-29

Similar Documents

Publication Publication Date Title
US20200040084A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
US20210269546A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
US20210317227A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
US20220064298A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
US20210147549A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
CA3105985A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
CA3155187A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
WO2020014545A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs